[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-dermatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,58,77,102,128,150,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100599603","ros-scavenging-nanozyme-combined-with-thermotherapy-alleviate-radiation-dermatitis-in-patients-with-head-and-neck-cancer-100599603",false,"NCT07086638","ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer","ROS-Scavenging Nanozyme Combined With Near-Infrared Thermotherapy for the Amelioration of Grade III Radiation Dermatitis in Patients With Head and Neck Cancer","Inclusion Criteria:\n\n1. Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;\n2. Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.\n\nExclusion Criteria:\n\n1. Eastern Cooperative Oncology Group performance status of \\>2;\n2. Pre-existing skin rash, ulceration or open wound in the treatment area;\n3. Known allergy to trolamine or prussian blue;\n4. Inflammatory or connective tissue disorder of the skin;\n5. History of head and neck radiotherapy.","ALL","18 Years","80 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"NA","Severe radiation dermatitis remains a challenging complication in head and neck cancer with limited treatment options; this study aims to evaluate a novel Prussian blue-based nanozyme combined with near-infrared thermotherapy to promote effective healing of Grade III lesions.",[27],"Radiation Dermatitis","RECRUITING","2026-04-14",{"date":31,"type":32},"2026-04-15","ACTUAL",{"date":34,"type":32},"2025-07-25",{"date":36,"type":21},"2026-10-25",{"name":38,"class":39},"West China Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":40},"100599175","ros-scavenging-amino-acid-derived-lipids-for-the-prevention-and-treatment-of-radiation-dermatitis-in-patients-with-head-and-neck-cancer-100599175","NCT07081074","ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer","Inclusion Criteria:\n\n1. Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;\n2. Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.\n\nExclusion Criteria:\n\n1. Eastern Cooperative Oncology Group performance status of \\>2;\n2. Pre-existing skin rash, ulceration or open wound in the treatment area;\n3. Known allergy to trolamine or amino acid;\n4. Inflammatory or connective tissue disorder of the skin;\n5. History of head and neck radiotherapy.",{"count":48,"type":21},40,[24],"Radiation dermatitis is a common complication in head and neck squamous cell carcinoma patients receiving radiotherapy. This study proposes an ROS-scavenging amino acid-based nanolipid to prevent oxidative skin damage. A multicenter randomized trial will evaluate its safety and efficacy in reducing dermatitis severity and improving treatment continuity.",[27],{"date":31,"type":32},{"date":54,"type":32},"2025-07-23",{"date":56,"type":21},"2026-12-23",{"name":38,"class":39},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":40},"100597906","novel-ros-scavenging-nanoenzymes-for-the-treatment-of-radiation-dermatitis-in-patients-with-head-and-neck-cancer-100597906","NCT07064577","Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer","Inclusion Criteria:\n\n1. Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;\n2. Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.\n\nExclusion Criteria:\n\n1. Eastern Cooperative Oncology Group performance status of \\>2;\n2. Pre-existing skin rash, ulceration or open wound in the treatment area;\n3. Inflammatory or connective tissue disorder of the skin;\n4. History of head and neck radiotherapy.",{"count":65,"type":21},30,[24],"There is no standard treatment for radiation dermatitis. In this study, the investigators have designed novel ROS-scavenging nanoenzymes and aim to evaluate their effectiveness in preventing radiation dermatitis in patients with head and neck cancer.",[27],"2025-08-03",{"date":71,"type":32},"2025-08-07",{"date":73,"type":32},"2025-07-15",{"date":75,"type":21},"2025-10-15",{"name":38,"class":39},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":40},"100598037","phase-3-modulating-the-skin-microbiome-to-prevent-radiation-dermatitis-in-breast-cancer-100598037","NCT07066280","Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer","Skin Repairing Cream for the Prevention of Radiation Dermatitis and Regulation of Skin Microbial Environment in Breast Cancer: A Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥18 and \\\u003C70 years, with pathologically confirmed breast cancer;\n\n  * TNM stage T1-3N1-3M0 or T3-4N0M0;\n\n    * Underwent mastectomy with or without implant reconstruction; ④ Medically fit for adjuvant radiotherapy (i.e., in good general condition to tolerate expected side effects such as fatigue, nausea, or vomiting); ⑤ No concurrent use of other skincare products throughout the study period;\n\n      * Voluntary participation with signed informed consent, agreeing to comply with investigator-directed use of the trial product.\n\nExclusion Criteria:\n\n* Prior history of radiotherapy;\n\n  * Severe systemic diseases (e.g., significant cardiac, hepatic, or renal dysfunction; immunocompromising conditions such as lymphoma, acquired immunodeficiency syndrome \\[AIDS\\], or Wiskott-Aldrich syndrome) or history of other malignancies; ③ Skin reactions due to systemic therapies (e.g., chemotherapy, immunotherapy) or active dermatologic conditions in the treatment area;\n\n    * Known hypersensitivity to the natural weak-acid macromolecular\u002Fsmall molecular repair cream or any of its components; ⑤ Current participation in other clinical trials or participation within the past 3 months, or judged by investigators to have poor compliance that would prevent completion of the study.","FEMALE","70 Years",{"count":87,"type":21},326,[89],"PHASE3","Acute radiation dermatitis (ARD) is the most common treatment-related adverse reaction following radiotherapy after modified radical mastectomy and\u002For prosthetic breast reconstruction in breast cancer patients. Moderate-to-severe ARD may compromise cosmetic outcomes and quality of life, and even impair radiotherapy efficacy. Current pharmacological prophylactic measures clinically employed - including topical corticosteroids, superoxide dismutase, and trolamine cream - demonstrate suboptimal efficacy and lack high-level evidence-based medical support. Emerging research indicates an association between cutaneous microbial homeostasis and ARD development, suggesting that maintaining skin surface acidity and modulating microecological balance may represent more effective preventive strategies.\n\nThis study evaluates the efficacy and safety of a natural weak-acid macromolecular\u002Fsmall molecular repair cream in preventing ARD among post-operative breast cancer patients receiving radiotherapy through skin microbiome modulation. We enrolled 326 high-risk early-stage breast cancer patients scheduled for post-operative radiotherapy and randomized them to compare the superiority of the natural weak-acid repair cream versus conventional care with moisturizer. Concurrent skin microbiome sampling was performed to assess microecological changes and their impact on ARD development. The findings will provide high-level clinical evidence and theoretical basis for the safer and more effective application of this natural weak-acid repair cream in preventing post-radiotherapy ARD in breast cancer patients.",[92,93,27],"Skin Microbiome","Breast Cancer","2025-07-04",{"date":73,"type":32},{"date":97,"type":32},"2025-04-10",{"date":99,"type":21},"2026-06",{"name":101,"class":39},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100586475","phase-3-topical-betamethasone-versus-moisturizer-in-preventing-radiation-dermatitis-in-large-breasted-patients-treated-in-the-prone-position-100586475","NCT06915857","Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position","A Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position: A Randomized Phase III Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Female.\n* Histological confirmation of breast malignancy (invasive or in situ carcinoma) or phyllodes.\n* Patients with large breasts \\[bra size 40 in and\u002For D cup or greater\\] and have undergone breast-conserving surgery.\n* Patients are scheduled to receive conventionally- (50Gy\u002F25#), hypo-fractionated (40Gy\u002F15#), or extreme hypo-fractionated (26Gy\u002F5#) photon-based radiation to whole or partial breast in prone position.\n* Patients treated with or without the addition of a boost.\n* Patient speaks English or can be aided by a translator.\n\nExclusion Criteria:\n\n* Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation.\n* Prior RT to any portion of the planned treatment site.\n* Active rash or pre-existing dermatitis within the treatment field.\n* Concomitant cytotoxic chemotherapy.\n* Unable to tolerate RT in prone.\n* Treatment involves use of tissue equivalent bolus.\n* Known sensitivity or allergy to betamethasone.\n* Known pregnancy.",true,{"count":111,"type":21},276,[89],"Radiotherapy (RT) is common in the treatment of breast cancer, however, 95% of breast cancer patients are at risk of developing acute and chronic skin toxicities known as radiation dermatitis (RD) which includes symptoms such as pruritus, edema, erythema, and moist desquamation (MD). Patients with a larger breast size are especially at risk of developing RD. The severity of RD can impact patient's quality of life (QOL) and their ability to complete treatment. Skin care guidelines for patients receiving RT vary and include barrier films and dressings, antibiotics, topical corticosteroids, and moisturizers. A study conducted at the Sunnybrook Odette Cancer Centre investigated the effectiveness of the prone treatment position during RT compared to the supine position. The results indicated that the prone position reduced the incidence of MD from 39.6% in supine to 26.9% in prone. However, 1 in 4 patients in the prone position still develop MD. Another study conducted at Sunnybrook Odette Cancer Centre found that Mepitel Film (MF), a barrier film, is more effective than the standard of care in preventing grade 2 or 3 RD, reducing the incidence of grade 2 or 3 RD from 45% to 15%. Despite its effectiveness, MF cannot be used for patients in the prone position and is costly. The topical corticosteroid betamethasone can prevent skin toxicity through its anti-inflammatory properties and is absorbed by the skin with minimal side effects. Betamethasone is cost-efficient and studies have found that it is effective in reducing the severity of RD in the supine position by half. Moreover, betamethasone can be applied in patients positioned in both prone and supine. The investigators hypothesize that adding betamethasone in large-breasted patients treated in prone during RT will further reduce RD.\n\nThis randomized control trial is the first of its kind to aim at investigating the effectiveness of betamethasone when compared with the standard of care in reducing the severity of RD in large-breasted patients being treated in the prone position during RT.\n\nThe investigators will enroll 276 breast cancer patients with band size ≥ 40 or ≥ D cup to be randomized to receive 0.1% betamethasone cream or the standard of care in a 2:1 ratio (alpha = 5% and power = 80% with the hypothesis that the addition of betamethasone to prone reduces the severity of RD from 30% to 15%). Upon enrolment, stratification factors will be recorded, and patients will be randomized into trial arms using procedures that balance stratification factors. All eligible patients will be stratified according to the following factors: patients receiving conventional RT (50Gy\u002F25#) versus hypofractionated RT (40Gy\u002F15#) versus extreme-hypofractionated RT (26Gy\u002F5#), whole or partial breast radiation, patients with Fitzpatrick skin type VI versus patients with Fitzpatrick skin type I-V, patients receiving a planned boost versus patients without planned boost. The CRA will be responsible for collection of assessments and photos from patients. Patients will use the assigned cream daily during RT treatment and up until 2 weeks after RT. The primary endpoint of this study is acute grade 2 or 3 toxicities as defined by the Common Terminology Criteria for Adverse Events v5.0. Secondary endpoints will include patient- and clinician-reported outcomes as assessed by the Skin Symptom Assessment and the Radiation-Induced Skin Reaction Assessment Scale. Moreover, the investigators will also employ a QOL tool, the Skindex-16, and a Patient Satisfaction Questionnaire. Patients will complete assessments weekly during RT and 2 weeks post-RT in person, followed by 6 weekly assessments and a 3-month telephone follow-up post-RT. Clinicians will assess patients weekly during RT and at the 2-week follow-up appointment.",[93,27],[116,117,118],"Topical","Betamethasone","Prone position","2025-05-16",{"date":121,"type":32},"2025-05-21",{"date":123,"type":32},"2025-02-26",{"date":125,"type":21},"2026-12-06",{"name":127,"class":39},"Sunnybrook Health Sciences Centre",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100572172","prospective-assessment-of-acute-skin-toxicities-in-breast-cancer-patients-undergoing-retreatment-with-40-gy-in-15-fractions-radiation-therapy-100572172","NCT06729814","Prospective Assessment of Acute Skin Toxicities in Breast Cancer Patients Undergoing Retreatment with 40 Gy in 15 Fractions Radiation Therapy","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Informed consent\n* Histological confirmation of breast malignancy (invasive or in situ carcinoma) or phyllodes\n* Previous history of ipsilateral breast cancer treated with RT\n* Patients are planned to receive hypofractionated (40Gy\u002F15) RT to the whole or partial breast or chest wall\n* Patients treated with or without the addition of a planned boost or bolus\n* Patients receiving local or locoregional radiation treatment\n* Can communicate in English or be aided by a translator\n\nExclusion Criteria:\n\n* Patients scheduled to receive conventionally fractionated (50Gy\u002F25 or 45Gy\u002F25) or extreme hypofractionation (26Gy\u002F5)\n* Patients planned to receive brachytherapy\n* Patients with active rash, pre-existing dermatitis, or other conditions within the treatment area that may make skin assessment for the study difficult per treating physician discretion\n* Concomitant cytotoxic chemotherapy\n* Scleroderma",{"count":65,"type":21},"OBSERVATIONAL","The most common cancer affecting Canadian women is breast cancer, with an estimated 1 in 8 women expected to be diagnosed with breast cancer during their lifetime. Improved screening and treatment have decreased mortality of breast cancer patients, however 14% of cancer-related deaths in Canadian women are still due to breast cancer. Common treatments for breast cancer include surgery, chemotherapy, hormone therapy, and radiation therapy (RT).\n\nDespite recent improvements in treatment and preventative screenings, 20% of breast cancer patients will develop local disease recurrence or another ipsilateral primary breast cancer. . The optimal treatment of recurrent or new primary breast cancers for patients who have undergone prior radiotherapy (RT) is not well-defined. Common treatment approaches consist of mastectomy or a second breast conserving surgery (BCS) with whole or partial breast reirradiation (reRT). In the past, mastectomy has been the preferred treatment for recurrent breast cancer due to concerns over serious acute and late skin toxicities that may result from additional reRT. Many of these late skin toxicities, such as fibrosis, are chronic and can result in patients experiencing pain or other negative impacts to quality of life (QOL).",[93,27],[139,140,141],"Prospective","acute skin toxicities","Quality of Life","2024-12-09",{"date":144,"type":32},"2024-12-11",{"date":146,"type":32},"2024-08-07",{"date":148,"type":21},"2026-08-07",{"name":127,"class":39},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100405547","epidermal-skin-grafts-to-improve-healing-in-radiation-wounds-100405547","NCT04560803","Epidermal Skin Grafts to Improve Healing In Radiation Wounds","Using Autologous Epidermal Skin Micrografts to Improve Healing In Radiation Wounds: A Pilot Study","Inclusion Criteria:\n\n* Status post radiation treatment, with radiation-induced wound. This includes patient with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations, this wound would otherwise be allowed to heal by secondary intention;\n* Having suitable areas of treatment: All wounds in the area of interest must be at least 20 cm2 (\\~10 cm2 per treatment\u002Fcontrol area);\n* The radiation injury must have a suitable adjacent irradiated control site before initiation of treatment. This will be determined by objective measurements of % wound epithelization, wound erythema, pliability, induration and thickness at enrollment;\n* Able and willing to comply with all visit, treatment and evaluation schedules and requirements;\n* Wound considered appropriate by physician to receive epidermal grafting;\n* Able to understand and provide written informed consent;\n\nExclusion Criteria:\n\n* Active tanning, including the use of tanning booths, during the course of the study;\n* Study wound exhibits clinical signs and symptoms of infection at the screening\u002Fenrollment visit;\n* Patient unable to provide donor site for epidermal harvesting;\n* Wound sites located on the face, hands or feet\n* Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;\n* History of collagen vascular disease;\n* Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex \u002F Zoster eruption within a year of study enrollment;\n* History of immunosuppression\u002Fimmune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications;\n* Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process);\n* Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;\n* Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study;\n* Participation in another interventional study with potential exposure to an investigational drug within past 30 days;\n* Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.",{"count":158,"type":21},34,[24],"Patients undergoing radiation for the treatment of malignancies may suffer from side effects to the skin in the form of radiation dermatitis. This can lead to local wound formation with poor healing. Treatment options for the resulting wound can range from watchful waiting to more aggressive debridement and secondary grafting.\n\nEpidermal grafting is a technique in which autologous epidermis is used to cover wounds that are larger than the donor site. Previous studies have demonstrated that this is an effective treatment for different wounds and ulcers but its utility has not yet been evaluated for the treatment of radiation induced injuries.\n\nThe CelluTome Epidermal Grafting System is a semi automated device that allows easy formation of epidermal Blister.\n\nOur study will evaluate the efficacy of epidermal grafts collected using the CelluTome device in the treatment of radiation dermatitis.",[27],[163,164,165],"Epidermal graft","Skin graft","Radiation wound","2023-10-20",{"date":168,"type":32},"2023-10-23",{"date":170,"type":32},"2021-01-19",{"date":172,"type":21},"2028-12",{"name":174,"class":39},"Massachusetts General Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":85,"enrollmentInfo":182,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":40},"100441776","the-association-between-radiation-dermatitis-and-skin-microbiome-in-breast-cancer-patients-100441776","NCT05032768","The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients","The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients Receiving Radiation After Mastectomy and Reconstructive Surgery","Inclusion Criteria:\n\n1. Female patients\n2. Invasive breast cancer confirmed by pathology\n3. Underwent mastectomy and breast reconstruction\n4. Radiotherapy after breast reconstruction\n5. ECOG score 0-1\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Previous breast or chest radiotherapy\n2. Other serious skin diseases (systemic lupus erythematosus, skin sclerosis, et al) and cannot receive radiotherapy\n3. Pregnant women\n4. Patients who are unwilling or unable to receive regular follow-up.",{"count":183,"type":21},100,"The breast cancer patients who received radiotherapy after mastectomy and breast reconstruction will be enrolled. The skin microbiome before radiotherapy and its changes after radiotherapy will be analyzed systematically to find out whether the skin microbiome is associated with the severity of radiation dermatitis.",[27,92,93,186],"Reconstructive Surgery","2021-09-01",{"date":189,"type":32},"2021-09-02",{"date":191,"type":32},"2021-01-01",{"date":193,"type":21},"2026-12-31",{"name":195,"class":39},"Fudan University"]